This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

ZAVICEFTA® (ceftazidime-avibactam): A safety and tolerability profile consistent with both cephalosporins and carbapenems1-4

Adverse Events

Special Warnings and Precautions for Use

Drug-drug interactions

Special warnings and precautions for use5

Hypersensitivity reactions5

Serious and occasionally fatal hypersensitivity reactions are possible. In case of hypersensitivity reactions, treatment with ZAVICEFTA must be discontinued immediately and adequate emergency measures must be initiated. 

Before beginning treatment, it should be established whether the patient has a history of hypersensitivity reactions to ceftazidime, to other cephalosporins or to any other type of β-lactam antibacterial agent. Caution should be used if ceftazidime/ avibactam is given to patients with a history of non-severe hypersensitivity to penicillins, monobactams or carbapenems. 

Clostridium difficile-associated diarrhoea5

Clostridium difficile-associated diarrhoea has been reported with ceftazidime/ avibactam and can range in severity from mild to life-threatening. 

This diagnosis should be considered in patients who present with diarrhoea during or subsequent to administration of ZAVICEFTA. 

Discontinuation of therapy with ZAVICEFTA and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given. 

Explore more

Quick Links

  • Patient Risk Factors

  • Pathogen Coverage

  • AMS Resources

Access case studies and videos

Prescribing information​​​​​​​

Zavicefta (ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion

Meronem® (meropenem triydrate) IV 1g

Meronem® (meropenem triydrate) IV 500mg

Tazocin® (piperacillin sodium, tazobactam sodium) 2g/0.25g Powder for Solution for Infusion

Tazocin® (piperacillin sodium, tazobactam sodium) 4g/0.5g Powder for Solution for Infusion

Amikacin (amikacin sulfate)  500mg/2ml solution for injection
Legal Category: Prescription Only Medicine (POM)
NHS Price: 5 vial pack £60.00
Click here for the Summary of Product Characteristics 

Tobramycin (tobramycin)
Tobramycin 240mg/6ml solution for injection
Legal Category: Prescription Only Medicine (POM) 
Basic NHS Cost: 1 vial £19.20
Click here for the Summary of Product Characteristics

Tobramycin 80mg/2ml solution for injection 
Legal Category: Prescription Only Medicine (POM) 
Basic NHS Cost: 5 vial £20.80
​​​​​​​Click here for the Summary of Product Characteristics

Gentamicin (gentamicin sulfate) 40 mg/ml Injection
Legal Category: Prescription Only Medicine (POM)
NHS Price: 5 vial £20.00 
Click here for the Summary of Product Characteristics

Ciprofloxacin (ciprofloxacin lactate) 2 mg/ml Solution for Infusion
Legal Category: Prescription Only Medicine (POM)
NHS Price: 10 bag £200.00 
Click here for the Summary of Product Characteristics

  1. Carmeli Y, et al. Lancet Infect Dis 2016;16:661–73.
  2. Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9.;
  3. Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62;
  4. Torres A, et al. Lancet Infect Dis 2018;18:285–95; 
  5. ZAVICEFTA. Summary of Product Characteristics;
  6. ​​​​​​​Mazuski JE, et al. Surg Infect 2017; 18:1-76.
PP-ZVA-GBR-0841. June 2021

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP

  • REPROVE Phase III trial (HAP/VAP)

  • RECLAIM Phase III trial (cIAI)

  • RECAPTURE Phase III trial (cUTI)​​​​​​​

  • REPRISE Phase III trial (cIAI and cUTI)

Alex Soriano

Infectious Disease Physician at Hospital Clinic in Barcelona, Spain, summarises key ZAVICEFTA data against other β-lactam/β-lactamase inhibitor combinations. He discusses ZAVICEFTA’s in vitro activity and broad-spectrum coverage against MDR P. aeruginosa and Enterobacteriaceae (including Klebsiella pneumoniae, Escherichia coli and ESBL-producing strains).

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?